Neumora Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $176.1M | $200.9M | $142.7M | $91.7M | — |
| Operating expenses | $241.2M | $263.5M | $252.1M | $135.9M | — |
| Operating income | -$241.2M | -$263.5M | -$252.1M | -$135.9M | — |
| Interest expense | $2.0M | $0 | — | — | — |
| Pretax income | -$236.8M | -$243.6M | -$235.7M | -$130.9M | — |
| Income tax expense | $130,000 | $178,000 | $268,000 | — | — |
| Net income | -$236.9M | -$243.8M | -$235.9M | -$130.9M | — |
| Balance Sheet | |||||
| Cash and equivalents | $182.5M | $142.1M | $374.0M | $240.9M | — |
| Current assets | $190.5M | $314.1M | $478.3M | $388.0M | — |
| Total assets | $191.0M | $317.0M | $496.2M | $426.2M | — |
| Current liabilities | $32.5M | $29.9M | $25.1M | $23.7M | — |
| Total liabilities | $87.2M | $29.9M | $27.1M | $29.4M | — |
| Total debt | $60.2M | — | — | — | — |
| Stockholders' equity | $103.9M | $287.1M | $469.1M | -$446.9M | -$325.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$206.4M | -$182.9M | -$163.3M | -$114.9M | — |
| Depreciation and amortization | $208,000 | $631,000 | $668,000 | $594,000 | — |
| Stock-based compensation | $29.9M | $40.0M | $17.2M | $8.3M | — |
| Capital expenditure | — | — | $117,000 | $511,000 | — |
| Free cash flow | — | — | -$163.4M | -$115.4M | — |
| Impairments | $595,000 | $0 | — | — | — |
Shares outstanding 185.3M · Free float 28.7%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.